Bromerguride

Bromerguride
Clinical data
Other names	2-Bromolisuride; 2-Br-LIS; Βromolisuride; Bromuride; ZK-95451; 3-(2-Βromo-9,10-didehydro-6-methyl-8α-ergolinyl)-1,1-diethylurea
Identifiers
	IUPAC name 3-[(6aR,9S)-5-bromo-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea;
CAS Number	83455-48-5;
PubChem CID	71266;
ChemSpider	64394;
UNII	HX58M2377W;
ChEMBL	ChEMBL2104211;
CompTox Dashboard (EPA)	DTXSID70232356 ;
Chemical and physical data
Formula	C20H25BrN4O
Molar mass	417.351 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3=C(NC4=CC=CC(=C34)C2=C1)Br)C;
	InChI InChI=1S/C20H25BrN4O/c1-4-25(5-2)20(26)22-12-9-14-13-7-6-8-16-18(13)15(19(21)23-16)10-17(14)24(3)11-12/h6-9,12,17,23H,4-5,10-11H2,1-3H3,(H,22,26)/t12-,17+/m0/s1; Key:SBHNNNRQZGYOAU-YVEFUNNKSA-N;

Bromerguride (INNTooltip International Nonproprietary Name), also known as 2-bromolisuride, is an antidopaminergic and serotonergic agent of the ergoline group which was described as having atypical antipsychotic properties but was never marketed.^[1]^[2]^[3]^[4]^[5] It was the first antidopaminergic ergoline derivative to be discovered.^[1] The pharmacodynamic actions of bromerguride are said to be "reversed"^[jargon] relative to its parent compound lisuride, a dopaminergic agent.^[6]

References

^ ^a ^b Wachtel H, Kehr W, Sauer G (December 1983). "Central antidopaminergic properties of 2-bromolisuride, an analogue of the ergot dopamine agonist lisuride". Life Sci. 33 (26): 2583–97. doi:10.1016/0024-3205(83)90342-9. PMID 6607392.
^ Krause W, Sauerbrey N, Gräf KJ (1986). "Pharmacokinetics and pharmacodynamics in man of the dopamine antagonist ergot derivative, bromerguride". Eur J Clin Pharmacol. 31 (2): 165–8. doi:10.1007/BF00606653. PMID 3803415. S2CID 25185807.
^ Fink H, Morgenstern R, Ott T (February 1991). "2-Bromolisuride, an ergot derivative, with dopamine antagonistic and serotonin agonistic properties". Pharmacol Biochem Behav. 38 (2): 321–5. doi:10.1016/0091-3057(91)90285-a. PMID 1905409. S2CID 46024181.
^ Assié MB, Cosi C, Koek W (September 1997). "5-HT_1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine". Eur J Pharmacol. 334 (2–3): 141–7. doi:10.1016/s0014-2999(97)01207-7. PMID 9369342.
^ Löschmann PA, Horowski R, Wachtel H (1992). "Bromerguride--an ergoline derivative with atypical neuroleptic properties". Clin Neuropharmacol. 15 Suppl 1 Pt A: 263A–264A. doi:10.1097/00002826-199201001-00137. PMID 1354031. S2CID 34842719.
^ Hilderbrand M, Hümpel M, Krause W, Täuber U (1987). "Pharmacokinetics of bromerguride, a new dopamine-antagonistic ergot derivative in rat and dog". Eur J Drug Metab Pharmacokinet. 12 (1): 31–40. doi:10.1007/BF03189859. PMID 3609071. S2CID 22838914.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.